MO50-6 Characterization of patients with advanced biliary tract cancer by KRAS alteration subtypes
Taro Shibuki(National Cancer Center Hospital East), Masato Ikeda(Boston Children's Hospital), T. Yoshino(National Cancer Center Hospital East), Takashi Matsumoto(Aso Iizuka Hospital), Naohiro Okano(Kyorin University), Akinori Asagi(Shikoku Cancer Center), Hidenori Bando(National Cancer Center Hospital East), Shinji Itoh(Kyushu University), M. Ueno(Kanagawa Prefectural Hospital Organization), Kumiko Umemoto(St. Marianna University School of Medicine), Tomomi Fujisawa(The University of Osaka), Y. Kawamoto(Hokkaido University Hospital), Masafumi Furukawa(National Hospital Organization Kyushu Cancer Center), Yuichi Nakamura(National Cancer Center Hospital East), Shin Shimizu(Saitama Cancer Center), Kenichi Sudo(Chiba Cancer Center), Nobuyuki Mizuno(Aichi Cancer Center), Taroh Satoh(Osaka University Hospital), K. Ohtsubo(Kanazawa University), Chigusa Morizane(Tokyo National Hospital)
Cited by 0
Related Papers
Futibatinib for <i>FGFR2</i> -Rearranged Intrahepatic Cholangiocarcinoma
|New England Journal of Medicine|2023|530
Feasibility and utility of a panel testing for 114 cancer‐associated genes in a clinical setting: A hospital‐based study
|Cancer Science|2019|375
Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies
|Nature Medicine|2020|366
Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
|Annals of Oncology|2019|333
Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study
|The Lancet. Gastroenterology & hepatology|2019|331